Multicenter Randomized Double-blind Comparative Study of Clinical Efficacy and Safety of GNR-069 (JSC "GENERIUM", Russia) and Nplate (Amgen Europe BV, The Netherlands) in Patients With Idiopathic Thrombocytopenic Purpura
Latest Information Update: 11 Mar 2024
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Sponsors GENERIUM Pharmaceuticals
Most Recent Events
- 05 Mar 2024 Status changed from recruiting to completed.
- 22 Feb 2023 Planned End Date changed from 3 Feb 2023 to 15 Jan 2024.
- 22 Feb 2023 Planned primary completion date changed from 4 Jan 2023 to 10 Nov 2023.